Natural and revolutionary tumor-specific T-cell therapy

IF 4.8 3区化学 Q1 CHEMISTRY, MEDICINAL Natural Products and Bioprospecting Pub Date : 2024-08-19 DOI:10.1007/s13659-024-00472-w

Zhi Dai, Xue-Meng Liu, Yun-li Zhao, Li-Xing Zhao, Xiao-Dong Luo

{"title":"Natural and revolutionary tumor-specific T-cell therapy","authors":"Zhi Dai, Xue-Meng Liu, Yun-li Zhao, Li-Xing Zhao, Xiao-Dong Luo","doi":"10.1007/s13659-024-00472-w","DOIUrl":null,"url":null,"abstract":"<div><p>Recently the FDA conducted a risk investigation and labeled the <b>Boxed Warning</b> for all BCMA- and CD19-directed CAR-T cell therapy, so does it mean that the public must take risk of secondary cancer to receive cell therapy? Here, without lentivirus and professional antigen presenting cell application, a novel tumor-specific T-cell therapy was successfully developed only by co-culturing MHC<sup>+</sup> cancer cells and Naïve-T cells under the CD28 co-stimulatory signals. These tumor-specific T-cells could be separated through cell size and abundantly produced from peripheral blood, and would spontaneously attack target cells that carrying the same tumor antigen while avoiding others in vitro test. Moreover, it markedly decreased 90% tumor nodules companying with greatly improving overall survival (76 days <i>vs</i> 30 days) after twice infusion back to mice. This work maximally avoided the risks of secondary cancer and non-specific killing, and might open a revolutionary beginning of natural tumor-specific T-cell therapy.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":"14 1","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333775/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Natural Products and Bioprospecting","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s13659-024-00472-w","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Recently the FDA conducted a risk investigation and labeled the Boxed Warning for all BCMA- and CD19-directed CAR-T cell therapy, so does it mean that the public must take risk of secondary cancer to receive cell therapy? Here, without lentivirus and professional antigen presenting cell application, a novel tumor-specific T-cell therapy was successfully developed only by co-culturing MHC⁺ cancer cells and Naïve-T cells under the CD28 co-stimulatory signals. These tumor-specific T-cells could be separated through cell size and abundantly produced from peripheral blood, and would spontaneously attack target cells that carrying the same tumor antigen while avoiding others in vitro test. Moreover, it markedly decreased 90% tumor nodules companying with greatly improving overall survival (76 days vs 30 days) after twice infusion back to mice. This work maximally avoided the risks of secondary cancer and non-specific killing, and might open a revolutionary beginning of natural tumor-specific T-cell therapy.

Graphical Abstract

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

天然、革命性的肿瘤特异性 T 细胞疗法。

最近，美国食品药品管理局（FDA）对所有BCMA和CD19导向的CAR-T细胞疗法进行了风险调查并标注了 "警示框"，这是否意味着公众接受细胞疗法必须承担继发性癌症的风险呢？在这里，在没有慢病毒和专业抗原提呈细胞应用的情况下，仅通过在CD28共刺激信号下将MHC+癌细胞和Naïve-T细胞共培养，就成功开发出了一种新型的肿瘤特异性T细胞疗法。这些肿瘤特异性 T 细胞可通过细胞大小进行分离，并从外周血中大量产生，在体外试验中会自发攻击携带相同肿瘤抗原的靶细胞，而不攻击其他细胞。此外，它还显著减少了 90% 的肿瘤结节，并大大提高了小鼠两次输注后的总生存期（76 天对 30 天）。这项工作最大限度地避免了继发性癌症和非特异性杀伤的风险，可能会为肿瘤特异性 T 细胞自然疗法开创一个革命性的开端。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊